Kalaris Therapeutics, Inc. Common Stock KLRS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $7.57M+25.6% | $7.16M+85.9% | $9.13M-74.7% | $8.44M+163% | $6.03M+207% | ||
| $4.26M-1.5% | $3.64M+11.0% | $3.62M+97.6% | $3.82M+291% | $4.32M+618% | ||
| $11.83M+14.3% | $10.8M+51.4% | $12.74M-66.3% | $12.26M+193% | $10.35M+304% | ||
| $11.83M+14.3% | $10.8M+51.4% | $12.74M-66.3% | $12.26M+193% | $10.35M+304% | ||
| -$11.83M-14.3% | -$10.8M-51.4% | -$12.74M+66.3% | -$12.26M-193% | -$10.35M-304% | ||
| $0-100% | $0-100% | $0-100% | $0-100% | $1.44M+1,750% | ||
| $977K+518% | $803K+105% | $847K+460% | $906K+162% | $158K+119% | ||
| -$10.86M-6.5% | -$10M+54.6% | -$11.89M+68.8% | -$11.35M-101% | -$10.2M-199% | ||
| -$0.46+81.7% | -$0.44+97.3% | -$0.64+97.7% | -$0.61+85.7% | -$2.52+3.1% | ||
| -$0.46+81.7% | -$0.44+97.3% | -$0.64+97.7% | -$0.61+85.7% | -$2.52+3.1% | ||
| 23.7M+485% | 15.3M+1,043% | 18.7M+1,283% | 18.7M+1,311% | 4.1M+209% | ||
| 23.7M+485% | 15.3M+1,043% | 18.7M+1,283% | 18.7M+1,311% | 4.1M+209% | ||
| $0-100% | $0-100% | $0-100% | $0-100% | $1.23M— | ||
| $0-100% | $0-100% | $0— | $0— | $365K— | ||
| $0+100% | $0+100% | $0— | $0+100% | -$186K+76.5% | ||
| -$10.91M-7.0% | -$10M+54.6% | -$11.89M+68.8% | -$11.35M-86.8% | -$10.2M+66.4% | ||
| -$55K— | —— | $6K— | —— | $0+100% | ||
| -$55K— | —— | $6K— | —— | $0+100% | ||
| $977K+406% | $803K+1,155% | $847K+2,632% | $906K+1,273% | $193K+615% | ||
| -$11.83M-14.3% | -$10.8M-51.4% | -$12.74M+66.3% | -$12.26M-193% | -$10.35M-304% | ||
| -$11.82M— | -$10.79M— | —— | —— | —— | ||
| -$11.82M— | -$10.79M— | —— | —— | —— | ||
| -$11.83M-14.3% | -$10.8M-51.4% | -$12.74M+66.3% | -$12.26M-193% | -$10.35M-304% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Kalaris Therapeutics, Inc. Common Stock profitable?
- Kalaris Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $44.1M over the trailing twelve months.
- What is Kalaris Therapeutics, Inc. Common Stock's earnings per share?
- Kalaris Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.15.
- Where does Kalaris Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.